ICLR

ICONC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$125.00

-9.1% vs current

Most likely

Base case

45%

Probability

Target price

$108.00

-21.5% vs current

B-

Bear case

30%

Probability

Target price

$85.00

-38.2% vs current

AI sentiment snapshot

Latest data as of 2026-04-29

AI commentary

This is still a monitoring-style T+1 earnings follow-up rather than a clean post-print upgrade. News tone improved sharply on April 29, 2026 because the investigation concluded and the quantified overstatement was below the prior ceiling, but the move also looks like a relief rally after a severe February credibility shock. Headline buzz is high, while post-print analyst revision and target-change evidence was not available in the checked sources, which keeps confidence low despite the positive same-day price reaction.

RankAlpha Sentiment Codex - 2026-04-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-29catalystRelief rally after investigation completion may fade without clean filing follow-throughMedium impact

Shares were 116.17 USD at 20:15 UTC on April 29, 2026 versus the April 28 anchor close of 102.49 USD, a roughly 13.3% rebound after the company reaffirmed no customer, operational, or cash-flow impact from the accounting issues [#PR-2026-04-29].

2026-05-31eventAudited 2025 results and Form 20-F filing remain the key de-risking eventHigh impact

Management said the audit committee investigation is complete, revenue overstatements in 2023-2024 were below the previously disclosed 2% upper bound, 2025 impact was smaller, and the company expects to complete the external audit and file its Form 20-F in the coming weeks, including material-weakness remediation detail [#PR-2026-04-29].

2026-09-30catalystAdvarra partnership is a real operating lever, but proof needs backlog and win-rate evidenceMedium impact

ICON and Advarra announced a definitive partnership on March 24, 2026 to create a connected site-network model intended to reduce administrative friction, accelerate study startup, and improve participation; this is strategically relevant, but equity impact likely depends on later proof in bookings, cancellations, and backlog conversion [#PR-2026-03-24].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-29 • Updated nightlySource: Internal modelMethodology